학술논문
Transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection: a double-blinded, phase 2 randomized, controlled trial
Document Type
article
Author
Shoham, Shmuel; Bloch, Evan M; Casadevall, Arturo; Hanley, Daniel; Lau, Bryan; Gebo, Kelly; Cachay, Edward; Kassaye, Seble G; Paxton, James H; Gerber, Jonathan; Levine, Adam C; Naeim, Arash; Currier, Judith; Patel, Bela; Allen, Elizabeth S; Anjan, Shweta; Appel, Lawrence; Baksh, Sheriza; Blair, Paul W; Bowen, Anthony; Broderick, Patrick; Caputo, Christopher A; Cluzet, Valerie; Cordisco, Marie Elena; Cruser, Daniel; Ehrhardt, Stephan; Forthal, Donald; Fukuta, Yuriko; Gawad, Amy L; Gniadek, Thomas; Hammel, Jean; Huaman, Moises A; Jabs, Douglas A; Jedlicka, Anne; Karlen, Nicky; Klein, Sabra; Laeyendecker, Oliver; Lane, Karen; McBee, Nichol; Meisenberg, Barry; Merlo, Christian; Mosnaim, Giselle; Park, Han-Sol; Pekosz, Andrew; Petrini, Joann; Rausch, William; Shade, David M; Shapiro, Janna R; Singleton, J Robinson; Sutcliffe, Catherine; Thomas, David L; Yarava, Anusha; Zand, Martin; Zenilman, Jonathan M; Tobian, Aaron AR; Sullivan, David J
Source
Clinical Infectious Diseases. 76(3)
Subject
Language
Abstract
BackgroundThe efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent plasma (CCP) for preventing infection in exposed, uninfected individuals is unknown. CCP might prevent infection when administered before symptoms or laboratory evidence of infection.MethodsThis double-blinded, phase 2 randomized, controlled trial (RCT) compared the efficacy and safety of prophylactic high titer (≥1:320 by Euroimmun ELISA) CCP with standard plasma. Asymptomatic participants aged ≥18 years with close contact exposure to a person with confirmed coronavirus disease 2019 (COVID-19) in the previous 120 hours and negative SARS-CoV-2 test within 24 hours before transfusion were eligible. The primary outcome was new SARS-CoV-2 infection.ResultsIn total, 180 participants were enrolled; 87 were assigned to CCP and 93 to control plasma, and 170 transfused at 19 sites across the United States from June 2020 to March 2021. Two were excluded for screening SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) positivity. Of the remaining 168 participants, 12/81 (14.8%) CCP and 13/87 (14.9%) control recipients developed SARS-CoV-2 infection; 6 (7.4%) CCP and 7 (8%) control recipients developed COVID-19 (infection with symptoms). There were no COVID-19-related hospitalizations in CCP and 2 in control recipients. Efficacy by restricted mean infection free time (RMIFT) by 28 days for all SARS-CoV-2 infections (25.3 vs 25.2 days; P = .49) and COVID-19 (26.3 vs 25.9 days; P = .35) was similar for both groups.ConclusionsAdministration of high-titer CCP as post-exposure prophylaxis, although appearing safe, did not prevent SARS-CoV-2 infection.Clinical trials registrationNCT04323800.